AstraZeneca Eliminates Advanced Colorectal Cancer Claim For Recentin
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
AstraZeneca will no longer file marketing applications in the U.S. and Europe this fall for Recentin (cediranib) in first-line metastatic colorectal cancer after the oral VEGF inhibitor failed to show an overall survival benefit in the Phase III HORIZON II study, the company announced May 28